project id: TCGA-PRAD; case submitter id: TCGA-G9-6343; selected normal wgs: true; state: released; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 0.94; rna integrity number: 7.1; age at index: 62; days to birth: -22843; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1946; age at diagnosis: 22843; ajcc clinical m: M0; ajcc clinical t: T2a; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 2450.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 3; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2008; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to sample procurement: 0; intermediate dimension: 0.6; longest dimension: 1.5; oct embedded: No; shortest dimension: 0.2; portion submitter id: TCGA-G9-6343-01A-21; percent lymphocyte infiltration: 1.0; percent monocyte infiltration: 0.0; percent necrosis: 5.0; percent neutrophil infiltration: 0.0; percent normal cells: 15.0; percent stromal cells: 10.0; percent tumor cells: 70.0; percent tumor nuclei: 75.0;